All sponsors

Daiichi Sankyo $4568.T

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS36
PHASE 3 / 2-320
RECRUITING21
READOUTS ≤12 MONTHS4
READOUT SLIPPED >6 MO43%

Delay Index: of 30 active trials registered more than a year ago, 13 have moved their primary completion (readout) date by more than 6 months since first registration (median +1.6 months). See all sponsors →

Open Daiichi Sankyo on the live radar map → 📅 $4568.T readout calendar (.ics)
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
Patritumab Deruxtecan (Fixed dose)
NCT04619004
P2Active, not recruitingNon-Small Cell Lung Cancer Metastatic; Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor2772022-11-21 (-12 mo)
Valemetostat Tosylate
NCT04703192
P2Active, not recruitingRelapsed/Refractory Peripheral T-Cell Lymphoma; Adult T Cell Leukemia/Lymphoma1552023-05-10 (-5 mo)
DS-1062a
NCT04656652
P3Active, not recruitingNon-small Cell Lung Cancer6052024-05-10 (+18 mo)
Patritumab Deruxtecan
NCT05338970
P3Active, not recruitingNonsquamous Non-small Cell Lung Cancer; EGFR L858R5862024-05-31 (-3 mo)
IDeate-Lung01
NCT05280470
P2Active, not recruitingExtensive-stage Small-cell Lung Cancer1872025-03-03 (+17 mo)
DS-8201a
NCT04622319
P3Active, not recruitingHER2-Positive Primary Breast Cancer; Residual Invasive Breast Cancer16002025-07-02 (-6 mo)
Trastuzumab deruxtecan
NCT04704934
P3Active, not recruitingGastric Cancer, Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma4902026-08-31 (+29 mo)
Ifinatamab deruxtecan (I-DXd)
NCT04145622
P1/2Active, not recruitingAdvanced Solid Tumor; Malignant Solid Tumor2472027-04-30 (+51 mo)
Quizartinib
NCT03793478
P1/2Active, not recruitingAcute Myeloid Leukemia652027-05-01
Ifinatamab deruxtecan
NCT06362252
P1/2RecruitingExtensive Stage-small Cell Lung Cancer1232027-07-20 (+8 mo)
Trastuzumab Deruxtecan
NCT05950945
P3RecruitingBreast Cancer2502027-10-01
IDeate-Lung02
NCT06203210
P3RecruitingSmall Cell Lung Cancer5402028-01-30 (+18 mo)
T-DXd
NCT06174987
P3RecruitingAdvanced Cancer; Metastatic Cancer752028-02-17 (+18 mo)
R-DXd
NCT06161025
P2/3RecruitingSolid Cancer8602028-02-29 (+2 mo)
valemetostat tosylate
NCT06644768
P1/2Active, not recruitingNon-small Cell Lung Cancer; Lung Cancer1372028-03-30
Trastuzumab Deruxtecan
NCT06731478
P3RecruitingGastric Cancer; Gastroesophageal Junction Cancer7262028-06-01
Ifinatamab deruxtecan
NCT06644781
P3RecruitingEsophageal Squamous Cell Carcinoma5102028-06-01 (-12 mo)
Bempedoic acid
NCT07474649
P3RecruitingCoronary Atherosclerosis; Mixed Dyslipidemia1032028-06-01
Quizartinib High Dose
NCT06824168
P2RecruitingAcute Myeloid Leukemia; Leukemia1302028-06-06
Ifinatamab deruxtecan
NCT06330064
P1/2RecruitingRecurrent or Metastatic Solid Tumors6802028-07-25 (+20 mo)
DS-3939a
NCT05875168
P1/2RecruitingAdvanced Solid Tumor; Metastatic Solid Tumor5902028-08-11 (+29 mo)
DO-01
NCT06819007
P3RecruitingOvarian Cancer5822028-11-01
Datopotamab Deruxtecan
NCT05555732
P3Active, not recruitingMetastatic Non Small Cell Lung Cancer12332029-05-11 (+21 mo)
Dato-DXd
NCT07129993
P2/3RecruitingUrothelial Cancer; Bladder Cancer6302029-06-01 (-8 mo)
R-DXd
NCT07791732
P3Not yet recruitingFallopian Tube Cancer; Primary Peritoneal Cancer6002029-07-01
Dato-DXd
NCT07890714
P1/2RecruitingUrothelial Cancer; Non-small Cell Lung Cancer2682029-09-30
Raludotatug deruxtecan
NCT06660654
P2Active, not recruitingAdvanced Solid Tumor; Metastatic Solid Tumors3352029-12-30 (+27 mo)
Trastuzumab Deruxtecan
NCT07022483
P3RecruitingEndometrial Cancer7102030-02-26 (-25 mo)
TROPION-Lung08
NCT05215340
P3Active, not recruitingMetastatic Non Small Cell Lung Cancer7402030-03-04 (+45 mo)
DESTINY-Lung06
NCT06899126
P3RecruitingNon-small Cell Lung Cancer6862030-04-24 (+2 mo)
QuANTUM-WILD
NCT06578247
P3Active, not recruitingLeukemia7002030-06-26
DB-Guide
NCT07683754
P3RecruitingAdvanced Breast Cancer; Metastatic Breast Cancer2002030-07-04
DS-3939a
NCT07739966
P1/2RecruitingSolid Tumor; Locally Advanced Non-Small Cell Lung Cancer4002030-07-31
HER3-DXd
NCT06172478
P2RecruitingAdvanced Solid Tumor; Melanoma8902030-11-19 (+65 mo)
DS3790a
NCT07220616
P1/2RecruitingHematological Malignancies; B-cell Non-Hodgkin Lymphoma4202030-11-30
Patritumab deruxtecan
NCT07701941
P1/2RecruitingHormone Receptor Positive; HER2-low or HER2-ultralow2202031-01-01